Efficacy of folic acid supplementation in stroke prevention: a meta-analysis
@article{Wang2007EfficacyOF, title={Efficacy of folic acid supplementation in stroke prevention: a meta-analysis}, author={Xiaobin Wang and Xianhui Qin and Hakan Demirtas and Jianping Li and Guangyun Mao and Yong Huo and Ningling Sun and Li-sheng Liu and Xiping Xu}, journal={The Lancet}, year={2007}, volume={369}, pages={1876-1882} }
570 Citations
Efficacy of Homocysteine-Lowering Therapy With Folic Acid in Stroke Prevention: A Meta-Analysis
- Medicine, PsychologyStroke
- 2010
Folic acid supplementation did not demonstrate a major effect in averting stroke, however, potential mild benefits in primary stroke prevention, especially when folate is combined with B vitamins and in male patients, merit further investigation.
Folic Acid Supplementation for Stroke Prevention in Patients With Cardiovascular Disease
- Medicine, BiologyThe American journal of the medical sciences
- 2017
Meta-analysis of folic acid efficacy trials in stroke prevention
- MedicineNeurology
- 2017
Folic acid supplementation could reduce the stroke risk in regions without folic Acid fortification, particularly in trials using a relatively low dosage of folic acid and with low vitamin B12 levels.
Effect of B-vitamin Supplementation on Stroke: a Meta-Analysis of Randomized Controlled Trials
- Medicine, PsychologyPloS one
- 2013
This study indicates that B-vitamin supplementation is not associated with a lower risk of stroke based on relative and absolute measures of association.
Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta‐Analysis of Randomized Controlled Trials
- MedicineJournal of the American Heart Association
- 2016
A greater benefit for CVD was observed among participants with lower plasma folate levels and without preexisting CVD and in studies with larger decreases in homocysteine levels, while folic acid supplementation had no significant effect on risk of coronary heart disease.
A Meta-Analysis of Folic Acid in Combination with Anti-Hypertension Drugs in Patients with Hypertension and Hyperhomocysteinemia
- MedicineFront. Pharmacol.
- 2017
Findings indicated that folic acid supplementation was effective in the primary prevention of CVCE among HT/HHcy patients, as well as reducing the blood pressure and total homocysteine levels.
Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels.
- Biology, MedicineThe American journal of cardiology
- 2010
The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: a randomized, placebo-controlled trial.
- MedicineInternational journal of cardiology
- 2010
References
SHOWING 1-10 OF 55 REFERENCES
Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials.
- MedicineJAMA
- 2006
Folic acid supplementation has not been shown to reduce risk of cardiovascular diseases or all-cause mortality among participants with prior history of vascular disease and several ongoing trials with large sample sizes might provide a definitive answer.
Secondary prevention with folic acid: effects on clinical outcomes.
- MedicineJournal of the American College of Cardiology
- 2003
Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials.
- MedicineThe American journal of clinical nutrition
- 2005
The objectives were to ascertain the lowest dose of folic acid associated with the maximum reduction in homocysteine concentrations and to determine the additional relevance of vitamins B-12 and B-6.
Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial.
- MedicineInternational journal of cardiology
- 2004
Homocysteine lowering with folic acid and B vitamins in vascular disease.
- MedicineThe New England journal of medicine
- 2006
Supplements combining folic acid and vitamins B6 and B12 did not reduce the risk of major cardiovascular events in patients with vascular disease.
Secondary prevention with folic acid: results of the Goes extension study
- MedicineHeart
- 2005
The results of an open label intervention study with folic acid in a population with stable coronary artery disease while taking stable statin treatment did not appear to attenuate the risk for recurrent events and longer follow up observations are necessary before definite conclusions can be made.
Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial.
- MedicineAmerican journal of epidemiology
- 1996
It is indicated that supplementation with a multivitamin/mineral combination may have reduced mortality from cerebrovascular disease and the prevalence of hypertension in this rural population with a micronutrient-poor diet.
Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease.
- MedicineJournal of the American Society of Nephrology : JASN
- 2004
A reverse relationship between tHcy and events in ESRD patients is found and administration of high-dose folic acid did not affect event rates.
Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study.
- MedicineArchives of internal medicine
- 2009
These randomized trial data from a large cohort of women at high risk of cardiovascular disease indicate that daily supplementation with folic acid, pyridoxine, and cyanocobalamin may reduce the risk of AMD.
Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients.
- Medicine, BiologyMedical science monitor : international medical journal of experimental and clinical research
- 2003
High-dose folic acid treatment did not improve outcome in hyperhomocysteinemia, and 88% of treated patients maintained higher than normal homocysteine levels, and there was a trend towards a decreased rate of cardiovascular events in treated participants as compared to untreated ones.